Global Brain Tumour Diagnosis and Treatment Market Size, Trend & opportunity Analysis Report, By Product Type (Primary Brain Tumor, Secondary Brain Tumor), By Diagnosis Type (CT scan, MRI, PET-CT scan, Molecular Testing, EEG), By Treatment Type (Surgery, Radiation Therapy, Targeted Therapy, Chemotherapy, Immunotherapy), End User (Hospitals, Ambulatory Surgical Centres) And Forecasts, 2025 -2035

The Primary Brain Tumor segment is the market leader, accounting for 58.4% of the global revenue share in 2024. This dominance is driven by the rising incidence of gliomas and meningiomas, alongside increased adoption of early diagnostic screening.

Magnetic Resonance Imaging (MRI) is the leading diagnostic modality, capturing a 34.9% market share in 2024. Its high-resolution, non-invasive capabilities make it indispensable for surgical planning and treatment monitoring.

Surgery remains the frontline treatment and the largest revenue contributor, holding a 36.7% market share in 2024. Growth in this segment is supported by advancements in minimally invasive techniques and neuronavigation systems.

North America dominates the global market with a 40.01% revenue share as of 2024. This leadership is attributed to cutting-edge healthcare infrastructure, a robust clinical trial network, and favorable reimbursement frameworks.

The Asia-Pacific region is identified as the fastest-growing market, with a projected CAGR of 8.7%. This growth is fueled by expanding healthcare infrastructure, government-led cancer screening initiatives, and rising awareness in countries like China, India, and Japan.

AI is transforming the market through powered imaging algorithms that improve early detection accuracy and automated tumor segmentation. Notable developments include GE HealthCare’s acquisition of MIM Software to enhance AI-powered imaging analytics for oncology.

The adoption of advanced treatments in low- and middle-income countries is hindered by high procedural costs, weak reimbursement policies, and limited healthcare infrastructure, such as the uneven distribution of specialist oncology centers.

Key players include Merck & Co., Siemens Healthineers, and GE HealthCare. Significant recent moves include AstraZeneca’s acquisition of Fusion Pharmaceuticals to strengthen its precision oncology pipeline and GE HealthCare’s acquisition of MIM Software.

TTFields are a non-invasive treatment modality for aggressive tumors like glioblastoma. In February 2024, the U.S. FDA expanded its approved indications, and recent partnerships (such as Novocure and Roche) are evaluating its use in combination with immunotherapy.